Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Which has better earnings & valuation, BMY or AMGN?

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.30B	2.01	-$8.95B	$2.67	17.84
Amgen	$33.42B	4.77	$4.09B	$10.96	27.08

Is BMY or AMGN more profitable?

Amgen has a net margin of 17.39% compared to Bristol Myers Squibb's net margin of 11.38%. Amgen's return on equity of 176.11% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	11.38%	87.62%	15.98%
Amgen	17.39%	176.11%	12.39%

Do institutionals and insiders hold more shares of BMY or AMGN?

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is BMY or AMGN a better dividend stock?

Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.2%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays out 92.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Amgen has raised its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do analysts recommend BMY or AMGN?

Bristol Myers Squibb currently has a consensus price target of $58.00, indicating a potential upside of 21.75%. Amgen has a consensus price target of $307.82, indicating a potential upside of 3.71%. Given Bristol Myers Squibb's higher probable upside, research analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	2 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.32
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35

Does the media prefer BMY or AMGN?

In the previous week, Amgen had 16 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 65 mentions for Amgen and 49 mentions for Bristol Myers Squibb. Amgen's average media sentiment score of 1.05 beat Bristol Myers Squibb's score of 0.98 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	34 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Amgen	47 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Which has more volatility & risk, BMY or AMGN?

Bristol Myers Squibb has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Summary

Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.